NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
124 hedge funds and large institutions have $246M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 62 increasing their positions, 21 reducing their positions, and 25 closing their positions.
44,067% more call options, than puts
Call options by funds: $1.32M | Put options by funds: $3K
195% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 21
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
3% less funds holding
Funds holding: 128 → 124 (-4)
5.64% less ownership
Funds ownership: 65.63% → 59.99% (-5.6%)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
64% less capital invested
Capital invested by funds: $690M → $246M (-$444M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$36.9M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.79M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.7M |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.64M |
| 5 |
Millennium Management
New York
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$23.5M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$12.5M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$11.1M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.75M |
NGM Hedge Fund Activity: Q4 2022 in Review
124 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q4 2022, worth a combined $246M — down 64% from $690M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of NGM and 24 opened new positions — a net loss of 1 holder — while 21 trimmed existing stakes and 62 added.
The largest buyer was EcoR1 Capital, adding an estimated $36.9M. The largest seller was Fidelity Investments, cutting an estimated $26.8M.
- 124 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q4 2022, down from 128 in Q3 2022.
- Funds reported $246M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q4 2022, down 64% quarter-over-quarter.
- 24 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q4 2022 and 25 closed out, a net change of -1 holder.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q4 2022 was EcoR1 Capital, an estimated $36.9M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $26.8M sold.
Based on aggregated 13F filings for Q4 2022.